Objectives This study aimed to estimate the gene loci associated with carcinogenesis of endocervical adenocarcinoma of uterus (EA) and metastasis. Study design Sixteen patients with EA were studied; 6 had nodal metast...Objectives This study aimed to estimate the gene loci associated with carcinogenesis of endocervical adenocarcinoma of uterus (EA) and metastasis. Study design Sixteen patients with EA were studied; 6 had nodal metastasis. DNA was extracted from EAs, and subjected to both conventional comparative genomic hybridization (CGH) and arraybased CGH. Copy number abnormalities were compared between cases with and without nodal metastasis. Results In all EAs, high frequencies of copy number losses were detected in genes LRP1B (on 2q21.2)-, DAB2 (5p13), and DCC (18q21.3), as well as regions 3p, 16q, and 22q, and copy number amplifications in genes NRAS (1p13.2), TOP2A (17q21-q22), NCOA3(AIB1) (20q12), and ARSA (22q tel). Nodal metastasis was associated with high frequencies of copy number loss in genes PGRMC2 and LAMA3 and amplification in CDK6 and NCOA3(AIB1). Conclusion This is the first report of gene copy number alterations spanning the whole genome in EA. These altered genes are speculated to be associated with EAs as a tumor suppressor and/or oncogene.展开更多
Objective. We assessed the antineoplastic effect and adverse reaction s of pacl itaxel monotherapy with paclitaxel 210 mg/m2 given every 3 weeks by 3-h infusio n on patients with endometrial cancer given as a 3-h infu...Objective. We assessed the antineoplastic effect and adverse reaction s of pacl itaxel monotherapy with paclitaxel 210 mg/m2 given every 3 weeks by 3-h infusio n on patients with endometrial cancer given as a 3-h infusion. Methods. This st udy was a multi-center, open-label phase II clinical trial of paclitaxel 210 m g/m2 given every 3 weeks by 3-h infusion. Patients with advanced or recurrent e ndometrial cancer were enrolled. The primary endpoint for efficacywas tumor resp onse rate. The secondary endpoints were duration of response and adverse drug re actions. Results. Among 23 patients evaluated for efficacy, partial remission (P R) was achieved in 7, no change (NC) in 10, progressive disease (PD) in 5, and n ot estimable (NE) in 1. The overall response ratewas 30.4%(7/23 cases). In seve n PR cases, median duration of response was 130 days (100-245 days). Subjective or objective symptoms ≥grade 3 included febrile neutropenia and constipation i n 8.7%(2/23 cases) each; and nausea, vomiting, fatigue, pain, urinary tract inf ection, lowered oxygen saturation, anorexia, arthralgia, myalgia, neuropathy, we ight loss, dyspnea, and need for red cell transfusion in 4.3%(1/23) each. Labor atory test abnormalities ≥grade 3 included neutropenia (78.3%, 18/23), leucope nia (47.8%, 11/23), lowered hemoglobin (13.0%, 3/23), decreased potassium (8.7 %, 2/23), and decreased sodium (4.3%, 1/23). All adverse reactions were succes sfully managed by prolonging treatment interval, dose reduction, interrupting ad ministration, discontinuation, and administration of G-CSF. Conclusion. Three- hour intravenous infusion of paclitaxel 210 mg/m2 is useful for endometrial canc er. Antineoplastic effect was achieved and adverse reactions were clinically man ageable.展开更多
Objective. To investigate the lymph node sites most susceptible to involvement relative to primary tumor histology in ovarian cancer. Methods. The locations of metastatic lymph nodes were investigated in 208 patients ...Objective. To investigate the lymph node sites most susceptible to involvement relative to primary tumor histology in ovarian cancer. Methods. The locations of metastatic lymph nodes were investigated in 208 patients with primary ovarian cancer who underwent systemic lymphadenectomy covering both the pelvic and para-aortic regions. Results. Lymph node metastasis was present in 12.8%(20/156) of patients with stage I (pT1M0), 48.6%(18/37) with stage II (pT2M0), and 60%(9/15) with stage III (pT3M0) disease, thus in 22.6%(47/208) of all study patients. Isolated para-aortic nodal involvement was present in 23.3%(14/60) of patients with serous tumor and 4.1%(6/148)-of those with non-serous tumor (P = 0.00002). In an analysis of 35 positive nodes from 25 patients with up to 3 positive nodes, 86.4%(19/22) of metastatic lymph nodes from patients with serous tumor were found in the para-aortic region, with 14 positive nodes located above the inferior mesenteric artery (IMA) and 5 below it, whereas metastasis to para-aortic lymph nodes accounted for 53.8%(7/13) of metastatic lymph nodes from patients with non-serous tumor (P = 0.0334). Conclusions. The locations of metastatic lymph nodes in ovarian cancer depend upon the histologic type of the primary cancer. In cases of serous tumor, the para-aortic region, particularly above the IMA, is the prime site for the earliest lymph node metastasis. However, the likelihood of pelvic node involvement is almost equal to that of para-aortic node involvement in cases of nonserous tumor.展开更多
文摘Objectives This study aimed to estimate the gene loci associated with carcinogenesis of endocervical adenocarcinoma of uterus (EA) and metastasis. Study design Sixteen patients with EA were studied; 6 had nodal metastasis. DNA was extracted from EAs, and subjected to both conventional comparative genomic hybridization (CGH) and arraybased CGH. Copy number abnormalities were compared between cases with and without nodal metastasis. Results In all EAs, high frequencies of copy number losses were detected in genes LRP1B (on 2q21.2)-, DAB2 (5p13), and DCC (18q21.3), as well as regions 3p, 16q, and 22q, and copy number amplifications in genes NRAS (1p13.2), TOP2A (17q21-q22), NCOA3(AIB1) (20q12), and ARSA (22q tel). Nodal metastasis was associated with high frequencies of copy number loss in genes PGRMC2 and LAMA3 and amplification in CDK6 and NCOA3(AIB1). Conclusion This is the first report of gene copy number alterations spanning the whole genome in EA. These altered genes are speculated to be associated with EAs as a tumor suppressor and/or oncogene.
文摘Objective. We assessed the antineoplastic effect and adverse reaction s of pacl itaxel monotherapy with paclitaxel 210 mg/m2 given every 3 weeks by 3-h infusio n on patients with endometrial cancer given as a 3-h infusion. Methods. This st udy was a multi-center, open-label phase II clinical trial of paclitaxel 210 m g/m2 given every 3 weeks by 3-h infusion. Patients with advanced or recurrent e ndometrial cancer were enrolled. The primary endpoint for efficacywas tumor resp onse rate. The secondary endpoints were duration of response and adverse drug re actions. Results. Among 23 patients evaluated for efficacy, partial remission (P R) was achieved in 7, no change (NC) in 10, progressive disease (PD) in 5, and n ot estimable (NE) in 1. The overall response ratewas 30.4%(7/23 cases). In seve n PR cases, median duration of response was 130 days (100-245 days). Subjective or objective symptoms ≥grade 3 included febrile neutropenia and constipation i n 8.7%(2/23 cases) each; and nausea, vomiting, fatigue, pain, urinary tract inf ection, lowered oxygen saturation, anorexia, arthralgia, myalgia, neuropathy, we ight loss, dyspnea, and need for red cell transfusion in 4.3%(1/23) each. Labor atory test abnormalities ≥grade 3 included neutropenia (78.3%, 18/23), leucope nia (47.8%, 11/23), lowered hemoglobin (13.0%, 3/23), decreased potassium (8.7 %, 2/23), and decreased sodium (4.3%, 1/23). All adverse reactions were succes sfully managed by prolonging treatment interval, dose reduction, interrupting ad ministration, discontinuation, and administration of G-CSF. Conclusion. Three- hour intravenous infusion of paclitaxel 210 mg/m2 is useful for endometrial canc er. Antineoplastic effect was achieved and adverse reactions were clinically man ageable.
文摘Objective. To investigate the lymph node sites most susceptible to involvement relative to primary tumor histology in ovarian cancer. Methods. The locations of metastatic lymph nodes were investigated in 208 patients with primary ovarian cancer who underwent systemic lymphadenectomy covering both the pelvic and para-aortic regions. Results. Lymph node metastasis was present in 12.8%(20/156) of patients with stage I (pT1M0), 48.6%(18/37) with stage II (pT2M0), and 60%(9/15) with stage III (pT3M0) disease, thus in 22.6%(47/208) of all study patients. Isolated para-aortic nodal involvement was present in 23.3%(14/60) of patients with serous tumor and 4.1%(6/148)-of those with non-serous tumor (P = 0.00002). In an analysis of 35 positive nodes from 25 patients with up to 3 positive nodes, 86.4%(19/22) of metastatic lymph nodes from patients with serous tumor were found in the para-aortic region, with 14 positive nodes located above the inferior mesenteric artery (IMA) and 5 below it, whereas metastasis to para-aortic lymph nodes accounted for 53.8%(7/13) of metastatic lymph nodes from patients with non-serous tumor (P = 0.0334). Conclusions. The locations of metastatic lymph nodes in ovarian cancer depend upon the histologic type of the primary cancer. In cases of serous tumor, the para-aortic region, particularly above the IMA, is the prime site for the earliest lymph node metastasis. However, the likelihood of pelvic node involvement is almost equal to that of para-aortic node involvement in cases of nonserous tumor.
